Providence-Led Team Represents Biohaven Pharmaceutical and BioShin Limited in BioShin's $60 Million Series A Preferred Equity Financing

A Locke Lord team led by Douglas Gray, Kathrine Morin (Providence) and Ralph Loren (Boston), represented Biohaven Pharmaceutical Holding Company (NYSE: BHVN) and its affiliate BioShin Limited in a $60 million Series A Preferred equity financing of BioShin Limited, Biohaven's subsidiary that is scheduled to exploit Biohaven intellectual property in the Asia-Pacific territory. The financing was led by OrbiMed Asia, with participation from Cormorant Asset Management LLC, HBM Healthcare Investments Ltd, Surveyor Capital (a Citadel Company) and Suvretta Capital Management, LLC. BioShin will advance Biohaven's clinical portfolio in the Asia-Pacific region, addressing migraine, neurologic and neuropsychiatric diseases. Additional assistance with the transaction was provided by Lori Basilico, (Providence), Stephen Murphy (Washington) and Jaremi Chilton (San Francisco).
Posted on September 29, 2020